Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,915 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1791
- Phase 1/Phase 2478
- Phase 3344
- Phase 4125
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia280
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts102
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,915 total
- NCT06324721Recruiting
Understanding arm swelling after breast cancer treatment
This study looks at why some people feel arm swelling (lymphedema) after breast cancer treatment even when tests don't show swelling. It follows people who are about to have breast surgery with lymph node removal and checks how they feel over time.
Leuven, Vlaams-BrabantAges 18 years+ - NCT06626672Recruiting
Digital Health Program for Kids with Heart Defects
This study uses digital tools to promote healthy habits in children (ages 8–14) with congenital heart disease. It aims to support both the child and their family in staying active and well.
MünchenAges 8–14 - NCT06725732RecruitingEarly Phase 1
Nebulized tranexamic acid for reducing bleeding during sinus surgery
This early-phase study tests if giving tranexamic acid (a medicine that helps blood clot) through a mist into the nose and sinuses during sinus surgery can reduce bleeding. It is designed for adults who are otherwise healthy and undergoing a common type of sinus surgery called functional endoscopic sinus surgery (FESS).
AsyutAges 18–65 - NCT06781450Recruiting
Study of immunotherapy for relapsed chest lymphoma
This study looks at how well two immunotherapy medicines—pembrolizumab alone or nivolumab combined with brentuximab vedotin—work for people with a type of lymphoma in the chest that has come back or not responded to treatment. It uses real-world data from patients who received these treatments outside of a clinical trial.
Bologna, BolognaAges 18 years+ - NCT06764459Recruiting
Study of FLT3 gene changes in AML patients
This trial looks at people with acute myeloid leukemia (AML) who have a change in a gene called FLT3. It aims to understand how this change affects the disease and how well treatments work.
BolognaAges 18 years+ - NCT07445984Recruiting
Gene testing for blood cancer patients
This study looks at gene patterns in people with blood cancers to better understand the disease and find possible treatments. If you are being tested for a blood cancer or have a blood cancer that came back or got worse, you may be able to join.
Parma, PRAges 1 year+ - NCT07448935Recruiting
Understanding a gene's role in AL amyloidosis and POEMS
This study looks at how a specific gene (IGLV1-44) affects two rare diseases: AL amyloidosis and POEMS syndrome. It involves a blood draw and possibly a bone marrow sample to learn more about how the gene works in these conditions.
PaviaAges 18–99 - NCT07446777Recruiting
Fasting and Mediterranean diet for multiple myeloma
This study tests whether a special diet—longer nightly fasting plus a Mediterranean eating pattern—can help people with multiple myeloma or its early stages. If you qualify, you will be randomly assigned to start the diet right away or join a waitlist group.
Miami, FloridaAges 18 years+ - NCT07451951Recruiting
Preventing Malnutrition in Infants: Comparing Two Nutrient Supplement Amounts
This study tests whether a small or medium amount of a special nutrient supplement can help prevent malnutrition in babies 6–12 months old. It is for families already in a support program (BISP/BNP) and aims to find the best dose to keep children healthy.
Peshawar, Khyber PakhtunkhwaAges 6 months–8 months - NCT07445438Recruiting
A multi-omics study for blood cancers
This study is testing whether a complete platform that analyzes multiple molecular levels (multi-omics) can be used to better understand and diagnose blood cancers (hematological malignancies). It looks at samples from the blood, bone marrow, and tissues to help with initial diagnosis or when cancer returns after treatment.
Parma, PRAges 2 years+ - NCT07445893Recruiting
Study of gecacitinib plus pegylated interferon for polycythemia vera
This trial tests a combination of two drugs—gecacitinib (a JAK inhibitor) and pegylated interferon—to see if they work better together for people with polycythemia vera (PV), a blood cancer that causes too many red blood cells. The study is for patients who have not tried these specific treatments before and who have symptoms like high blood counts, weight loss, night sweats, or an enlarged spleen.
BeijingAges 18 years+ - NCT07448779Recruiting
A study on N-glycosylation and its role in AL amyloidosis
This research study looks at how certain sugar molecules (N-glycosylation) on proteins may play a role in a disease called AL amyloidosis. Researchers will study blood samples from people with related plasma cell disorders to learn more about these sugars, which could help with diagnosis and treatment.
Pavia, PVAges 18–99 - NCT07451652RecruitingPhase 2
Low dose epcoritamab plus chemotherapy for relapsed lymphoma
This trial tests a combination of a lower dose of the immunotherapy drug epcoritamab with standard chemotherapy (GemOx) for people with a type of lymphoma called DLBCL that has come back or not responded to previous treatment. The goal is to see if this combination can help get the lymphoma under control before a stem cell transplant (using your own cells).
Monterrey, Nuevo LeónAges 18–65 - NCT07453095RecruitingPhase 2
Glofitamab for mantle cell lymphoma after CAR T-cell therapy
This trial tests a new drug called glofitamab for people with mantle cell lymphoma (MCL) whose cancer did not respond or came back after CAR T-cell therapy. Glofitamab is a type of immunotherapy that helps your immune system fight the cancer.
AlessandriaAges 18 years+ - NCT07448324RecruitingPhase 2
Orelabrutinib plus rituximab with or without lenalidomide for untreated MZL
This trial tests a combination of targeted drugs for people with a type of lymphoma called marginal zone lymphoma (MZL) that has not been treated before. The drugs attack cancer cells in different ways, and the treatment plan may adjust based on how you respond.
Nanjing, JiangsuAges 18 years+ - NCT07451054RecruitingPhase 1
Stem cells plus CAR T-cells for lymphoma
This trial tests a new treatment that combines your own stem cells with special immune cells (CAR T-cells) that target a marker called CD45 on lymphoma cells. It may help people whose lymphoma has not responded to multiple prior therapies.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07450872Recruiting
Gut health and symptoms in childhood cancer survivors
This study looks at how cancer survivors' symptoms (like pain, fatigue, or mood) are connected to the bacteria living in their gut. It aims to understand why some children have different symptom patterns after treatment, which could help doctors provide better care.
Hangzhou, ZhejiangAges 8–18 - NCT07451912RecruitingPhase 1/Phase 2
Venetoclax Combo for CEBPA-Mutated AML in Unfit Patients
This trial tests a combination of three drugs (venetoclax, a hypomethylating agent, and low-dose cytarabine) for people with newly diagnosed AML that has a CEBPA gene mutation and who are not strong enough for standard intensive chemotherapy. The goal is to see if this gentler approach works well.
Suzhou, JiangsuAges 18 years+ - NCT07453368RecruitingPhase 2
Orelabrutinib for relapsed or hard-to-treat AIHA
This trial tests a targeted pill called orelabrutinib for people with autoimmune hemolytic anemia (AIHA) that has come back or not responded to standard treatments. It may help control your immune system's attack on your red blood cells.
Beijing, Beijing MunicipalityAges 18–85 - NCT07452575Enrolling by invitation
3D ultrasound to check ankle bleeds in hemophilia
This study tests whether a 3D ultrasound can better see and check ankle joint bleeding in people with hemophilia or other bleeding disorders. It may help doctors find and treat ankle bleeds more quickly, which could protect the joint.
Toronto, OntarioAges 5–18 - NCT07450040Enrolling by invitation
Tislelizumab plus chemo for early-stage NK/T-cell lymphoma
This trial tests a combination of the immunotherapy drug tislelizumab with two chemotherapy drugs (gemcitabine and peraspartase) for people with newly diagnosed stage I or II NK/T-cell lymphoma. The goal is to see if this combination works well and is safe.
Shanghai, ChinaAges 18–70 - NCT07445347Enrolling by invitation
Bevacizumab for severe HHT liver issues with high heart output
This study looks at how well the drug Bevacizumab works and how safe it is for people with HHT who have severe liver problems that cause their heart to pump too much blood. It aims to help doctors understand if this treatment can help manage these serious symptoms.
PoitiersAges 18 years+ - NCT07446491RecruitingPhase 1/Phase 2
PN20 for low platelets in liver disease patients needing a procedure
This study tests a new medicine called PN20 to safely raise platelet counts in people with chronic liver disease who need a minor procedure (like a biopsy). It's for patients whose platelet count is below 50 and whose liver disease is not too severe.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07452198RecruitingPhase 3
Study of new drug for relapsed or hard-to-treat multiple myeloma
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
TianjinAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,915 recruiting hematology studies from the U.S. registry right now, out of 7,288 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.